October 12, 2011 by staff
Arthritis Treatment, Arthritis Care UK provides support to treatment with tocilizumab. National Institute for Health and Clinical Excellence (NICE) recommendations that tocilizumab should be more readily available for patients with arthritis have gained the support of Arthritis Care in the UK.
In 2010, Nice recommends tocilizumab as a way to treat people with arthritis if there has been an inadequate response to one or more TNF inhibitors and rituximab, which has also produced an inadequate response.
The drug is also recommended in the rituximab is contraindicated or has produced undesirable side effects.
Moscogiuri Federico, head of policy & campaigns Arthritis Care UK, said: “Although it is noteworthy that this guide is only preliminary, it represents a very encouraging in terms of improving treatment options for people with rheumatoid arthritis. ”
The Nice draft guidelines also specify that tocilizumab only be used in an early stage in the way of treating rheumatoid arthritis specific clinical circumstances, and only if the manufacturer offers tocilizumab with the discount plan agreed as part of access the patients.
Please feel free to send if you have any questions regarding this post , you can contact on
Disclaimer: The views expressed on this site are that of the authors and not necessarily that of U.S.S.POST.